Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease

References

• Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003 Jun;991:1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12846969 [cited 11 Jun 2013]
   PubMed Web of Science ®Google Scholar
• Schnitzler A, Gross J. Normal and pathological oscillatory communication in the brain. Nat Rev Neurosci. 2005 Apr;6(4):285–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15803160 [cited 15 Jun 2011].
   PubMed Web of Science ®Google Scholar
• Giovanni G, Di Matteo V, Esposito E. Birth, life and death of dopaminergic neurons in the substantia nigra. New York: Springer; 2009.
   Google Scholar
• Schulz-Schaeffer WJ. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010 Aug;120(2):131–43.
   PubMed Web of Science ®Google Scholar
• Recchia A, Debetto P, Negro A, et al. α-Synuclein and Parkinson's disease. FASEB J. 2004 Jan;18(6):617–26.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun;276(5321):2045–7.
   PubMed Web of Science ®Google Scholar
• Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18(2):106–8.
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.J Neurosci. 2002 Apr 1;22(7):2780–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11923443
   PubMed Web of Science ®Google Scholar
• Gaugler MN, Genc O, Bobela W, et al. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012;123(5):653–69.
   PubMed Web of Science ®Google Scholar
• Lundblad M, Decressac M, Mattsson B, et al. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci. 2012 Feb;109(9):3213–9.
   PubMed Web of Science ®Google Scholar
• Decressac M, Mattsson B, Lundblad M, et al.. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012 Mar;45(3):939–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22182688 [ cited 2012 Nov 21].
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec;351(24):2498–508.
   PubMed Web of Science ®Google Scholar
• Cutson TM, Laub KC, Schenkman M. Pharmacological and nonpharmacological interventions in the treatment of Parkinson's disease. Phys Ther. 1995 Jan;75(5):363–73.
   PubMed Web of Science ®Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, et al. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009 Jan;8(1):67–81.
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Treatment options in the modern management of Parkinson disease. Arch Neurol. 2007 Aug;64(8):1083–8.
   PubMedGoogle Scholar
• Morgante L, Morgante F, Moro E, et al. How many Parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007 Dec;13(8):528–31.
   PubMed Web of Science ®Google Scholar
• Fuentes R, Petersson P, Siesser WB, et al. Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science. 2009 Mar;323(5921):1578–82. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2669752&tool=pmcentrez&rendertype=abstract [cited 17 Oct 2012].
   PubMed Web of Science ®Google Scholar
• Santana M., Halje P., Simplício H et al. Spinal cord stimulation alleviates motor symptoms in a primate model of Parkinson's disease. Neuron. 2014:1–7. (Accepted).
   Web of Science ®Google Scholar
• Thevathasan W, Mazzone P, Jha A, et al. Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson disease. Neurology. 2010 Apr;74(16):1325–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2860483&tool=pmcentrez&rendertype=abstract [cited 17 Nov 2011].
   PubMed Web of Science ®Google Scholar
• Fénelon G, Goujon C, Gurruchaga J-M, et al. 2012. 2016Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism & Related Disorders. New York: Elsevier Ltd.; p. 213–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21865071 [cited 20 Oct 2011 ].
   Google Scholar
• Agari T, Date I. Spinal cord stimulation for the treatment of abnormal posture and gait disorder in patients with Parkinson’ s disease. Neurol Med Chir (Tokyo). 2012;52:470–4.
   PubMed Web of Science ®Google Scholar
• Landi A, Trezza A, Pirillo D, et al. Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease. Neuromodulation Technol Neural Interface. 2013;16(3):276–9.
   PubMed Web of Science ®Google Scholar
• Hassan S, Amer S, Alwaki A, et al. A patient with Parkinson's disease benefits from spinal cord stimulation. J Clin Neurosci. 2013 Aug;20(8):1155–6. Available from: http://dx.doi.org/10.1016/j.jocn.2012.08.018 [cited 7 Mar 2013].
   PubMed Web of Science ®Google Scholar
• Nishioka K, Nakajima M. Beneficial therapeutic effects of spinal cord stimulation in advanced cases of Parkinson's disease with intractable chronic pain: a case series. Neuromodulation Technol Neural Interface. 2015. Available from: http://doi.wiley.com/10.1111/ner.12315
   PubMed Web of Science ®Google Scholar
• Arii Y, Sawada Y, Kawamura K, et al. Immediate effect of spinal magnetic stimulation on camptocormia in Parkinson's disease.J Neurol Neurosurg Psychiatry. 2014 Apr Available from: http://www.ncbi.nlm.nih.gov/pubmed/24780955 [ cited 30 Sep 2014].
   PubMed Web of Science ®Google Scholar
• Yadav AP, Fuentes R, Zhang H, et al. Chronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions. Sci Rep. 2014 Jan;4:3839. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3899601&tool=pmcentrez&rendertype=abstract [ cited 20 Feb 2014].
   PubMed Web of Science ®Google Scholar
• Shinko A, Agari T, Kameda M, et al. Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease. PLoS One. 2014 Jan;9(7):e101468. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4092020&tool=pmcentrez&rendertype=abstract [cited 9 Oct 2014].
   PubMed Web of Science ®Google Scholar
• Löw K, Aebischer P, Schneider BL. Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles. Hum Gene Ther. 2013;24(6):613–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23600720
   PubMed Web of Science ®Google Scholar
• Dusonchet J, Bensadoun JC, Schneider BL, et al. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol Dis. 2009;35(1):32–41.
   PubMed Web of Science ®Google Scholar
• Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol. 1998 Aug;152(2):259–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9710526
   PubMed Web of Science ®Google Scholar
• Koprich JB, Johnston TH, Reyes MG, et al. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pat. Mol Neurodegener; 2010;5(1):43. Available from: http://www.molecularneurodegeneration.com/content/5/1/43
   PubMed Web of Science ®Google Scholar
• Eusebio A, Brown P. Oscillatory activity in the basal ganglia. Parkinsonism Relat Disord. 2007 Jan;13 Suppl 3:S434–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18267278
   PubMed Web of Science ®Google Scholar
• Costa RM, Lin S, Sotnikova TD, et al. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron. 2006 Oct;52(2):359–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17046697 [cited 12 Jul 2012].
   PubMed Web of Science ®Google Scholar
• Baba T, Kameda M, Yasuhara T, et al. Electrical stimulation of the cerebral cortex exerts antiapoptotic, angiogenic, and anti-inflammatory effects in ischemic stroke rats through phosphoinositide 3-kinase/Akt signaling pathway. Stroke. 2009;40(11):e598–605. Available from: http://stroke.ahajournals.org/lookup/doi/10.1161/STROKEAHA.109.563627
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Shingo T, Kobayashi K, et al. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease. Eur J Neurosci. 2004 Mar;19(6):1494–504.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003 Jun;9(6):669–76.
   PubMed Web of Science ®Google Scholar
• Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue—beyond blood vessels. Exp Neurol. 2004 Jun;187(2):246–53.
   PubMed Web of Science ®Google Scholar
• Prewitt CMF, Niesman IR, Kane CJM, et al. Activated macrophage/microglial cells can promote the regeneration of sensory axons into the injured spinal cord. Exp Neurol. 1997 Dec;148(2):433–43.
   PubMed Web of Science ®Google Scholar
• Becker D, Gary DS, Rosenzweig ES, et al. Functional electrical stimulation helps replenish progenitor cells in the injured spinal cord of adult rats. Exp Neurol. 2010 Apr;222(2):211–8.
   PubMed Web of Science ®Google Scholar